Paid Clinical Trials El Paso
Discover 803 paid clinical trials in El Paso, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
BMS-986365 vs. Investigator's ChoiceA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Sponsor:
Celgene
Location:
Code:
NCT06764485
Conditions
Metastatic Castration-resistant Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BMS-986365
Enzalutamide
Abiraterone
Docetaxel
Predinsone/Prednisolone
IDE196 & CrizotinibIDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
Sponsor:
IDEAYA Biosciences
Location:
Code:
NCT05987332
Conditions
Metastatic Uveal Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IDE196
Crizotinib
Pembrolizumab
Ipilimumab
Nivolumab
AnifrolumabA 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Sponsor:
AstraZeneca
Location:
Code:
NCT06015737
Conditions
Cutaneous Lupus Erythematosus
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Anifrolumab
Placebo
LY3962673MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06586515
Conditions
Pancreatic Ductal Adenocarcinoma
Non-small Cell Lung Cancer
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LY3962673
Cetuximab
Gemcitabine
nab-paclitaxel
Oxaliplatin
INBRX-109Study of INBRX-109 in Conventional Chondrosarcoma
Sponsor:
Inhibrx Biosciences, Inc
Location:
Code:
NCT04950075
Conditions
Conventional Chondrosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
INBRX-109
Placebo
Interested in new trials?
Get alerts for new trials in your area by subscribing now
NX-2127A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Sponsor:
Nurix Therapeutics, Inc.
Location:
Code:
NCT04830137
Conditions
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Waldenstrom Macroglobulinemia (WM)
Mantle Cell Lymphoma (MCL)
Marginal Zone Lymphoma (MZL)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NX-2127
SonrotoclaxA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenstr├╢m Macroglobulinemia
Sponsor:
BeiGene
Location:
Code:
NCT05952037
Conditions
Waldenstrom Macroglobulinemia
Waldenstrom's Macroglobulinemia Recurrent
Waldenstrom's Macroglobulinemia Refractory
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sonrotoclax
Zanubrutinib
TagraxofuspTagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium
Location:
Code:
NCT05476770
Conditions
Hematologic Malignancy
AML
ALL
BPDCN
MDS
Eligibility Criteria
Sex: All
Age: 1 - 21
Healthy Volunteers: Not accepted
Interventions
Tagraxofusp
Fludarabine
Cytarabine
Dexamethasone
Vincristine
RLY-2608 & FulvestrantFirst-in-Human Study of Mutant-selective PI3K╬▒ Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
Sponsor:
Relay Therapeutics, Inc.
Location:
Code:
NCT05216432
Conditions
PIK3CA Mutation
Solid Tumor, Adult
HER2-negative Breast Cancer
Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RLY-2608
Fulvestrant
Palbociclib 125mg
Ribociclib 400mg
Ribociclib 600mg
Observational StudyEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Sponsor:
Virginia Commonwealth University
Location:
Code:
NCT03981575
Conditions
Myotonic Dystrophy 1
DM1
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted